BioSpace News Archive

IMUNON, Inc. announces that Jean Boyer, Ph.D., vice president of preclinical research and development, will highlight the Company’s vaccine development work in a presentation at the Vaccines Summit-2023 underway in Boston.

Shattuck Labs, Inc. announced that company management will participate in the 6th Annual Evercore ISI HealthCONx Conference being held November 28-30, 2023.

Mayo Clinic Laboratories and Progentec Diagnostics announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market.

Centinel Spine®, LLC announced the adoption of Carleon’s Clinical Appropriateness Guidelines-Musculoskeletal Spine Surgery Criteria by the largest payers in Illinois, Texas, New Mexico, and Oklahoma—representing over 14 million covered lives.

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD.

Zeteo Tech, Inc. announced the issuance of U.S. Patent No. 11658021, titled “Systems and Methods of Rapid and Autonomous Detection of Aerosol Particles.”.

IgGenix, Inc. published new data as part of an international collaboration on the role of human monoclonal IgE antibodies in peanut allergy.

TRex Bio, Inc. today announced the selection of development candidate TRB-061, an agonist targeting TNF receptor 2 (TNFR2). TRB-061 expands regulatory T cells (Tregs) to restore homeostasis in the tissue at the site of inflammation.

Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation System, announced the completion of the 100th implant of its Neuspera System as part of the SANS-UUI Phase II clinical trial.

AriBio Co., Ltd. announces the global expansion of the POLARIS-AD study, a phase 3 early Alzheimer’s disease trial into the European Union, United Kingdom, Korea and China.